Pathological Mechanism and Targeted Drugs of COPD
Peng Guo,Rui Li,Tie Hua Piao,Chun Lan Wang,Xiao Lu Wu,Hong Yan Cai
DOI: https://doi.org/10.2147/COPD.S366126
2022-07-12
International Journal of COPD
Abstract:Peng Guo, 1 Rui Li, 2 Tie Hua Piao, 3 Chun Lan Wang, 3 Xiao Lu Wu, 3 Hong Yan Cai 3 1 College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Changchun, 130000, People's Republic of China; 2 Graduate School, Beijing University of Chinese Medicine, Beijing, 100000, People's Republic of China; 3 Pulmonology Department, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, Changchun, 130000, People's Republic of China Correspondence: Hong Yan Cai, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, Changchun, 130000, People's Republic of China, Email Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis, emphysema, and small airway obstruction. Incompletely reversible airflow limitation, inflammation, excessive mucus secretion and bronchial mucosal epithelial lesions are the main pathological basis of the disease. The prevalence of COPD is increasingly worldwide, which has caused the burden on individuals and society. This paper summarizes the pathogenesis of COPD and clarifies the effect and mechanism of the latest targeted drugs for COPD. Besides, we focus on NOD-like receptor thermal protein domain associated protein 3 inflammasome (NLRP3 inflammasome). NLRP3 can promote production of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3 is an important factor in the migratory aggregation of macrophages and neutrophils and the generation of oxidative stress. Inhibition of NLRP3 inflammasome indirectly blocks the inflammatory effects of IL-1β and IL-18, which may be regarded as an ideal target for COPD treatment. Keywords: chronic obstructive pulmonary disease, pathogenesis, targeted drugs, NLRP3 COPD is an incurable chronic lung disease, which is also complicated by pulmonary heart disease and respiratory failure in some individuals with a tremendous burden on individuals and society. At present, it is not clear whether the pathological mechanisms of COPD are mainly thought to be the result of genetic and environmental interactions. Moreover, smoking is considered to be the main environmental factor to trigger COPD. 1–3 Except for genetics, gender, 4 occupation, 4,5 airway hyperresponsiveness, 6 lung growth and development, 3,7 and infection 8 also play an important role in the development of COPD. It is easily understood that gender may influence the history of smoking and the particulate environment in which the occupation is located. However, the status of lung growth and development determines the susceptibility to COPD, which seems to have a close relationship with genetics. 9,10 We should focus on airway hyperreactivity, which is an independent predictor of COPD and can exist independently without asthma and bronchitis, suggesting that the inflammatory response in COPD is different from asthma. 6,11 In addition to the above causes, inflammatory mechanisms, oxidative stress, and protease-antiprotease imbalance are also involved in the development of COPD. Various reasons for bronchial mucosal epithelial cell degeneration, necrosis, squamous metaplasia and recurrent injury-repair airway wall eventually lead to the occurrence of structural repeated remodeling of the airways and scar formation. 12,13 Currently, there is still no specific treatment for COPD, and palliative regimens to improve airflow limitation are the mainstay methods. We generally do not advocate drug intervention for COPD in the stable period, but in the acute attack stage, antibiotics, inhaled corticosteroids, bronchodilators, and other medicines are widely used in clinical practice. However, the negative effects of these drugs should not be ignored. For example, frequent use of inhaled corticosteroids can cause side effects such as osteoporosis, immunosuppression and increased probability of infection, especially infection that promotes the recurrence of COPD, 8,14 while bronchodilators, for example, the anticholinergic agents and β2 agonists commonly used in clinical practice have side effects such as heart rate disturbance, impact on vision, urinary retention, and metabolic disorders, which cannot be ignored. 15,16 With the development of molecular biology, targeted drugs for treatment by blocking COPD development are gradually being developed. This paper not only reviews the pathogenesis of COPD and the pharmacological mechanisms of COPD-related targeted drugs but also elaborates the concerned contribution of NLRP3 to COPD and the effectiveness of NLRP3 inhibitors and related advances. Oxidative stress is involved in the development of several inflammatory conditions and is an important pathogenetic factor in COPD. Sti -Abstract Truncated-
English Else